SPR Therapeutics to Present Clinical Trial and Real-World Findings at ASPN 2022
CLEVELAND, July 14, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced today that two presentations highlighting SPRINT® PNS in treating chronic...
Neuroscience
Pasithea Therapeutics Awarded a Drug Development Research Grant
-- AUD $1 million (U.S $694,000) grant transferred as part of Alpha-5 Integrin, LLC transaction ---- Provides approximately U.S. $694,000...
Measuring Subtypes of Concussion with EYE-SYNC
Over the past two years, many of the world’s foremost researchers and leading clinical experts from across the United States have...